Literature DB >> 20383179

Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer.

Vathany Kulasingam1, Maria P Pavlou, Eleftherios P Diamandis.   

Abstract

Despite widespread interest, few serum biomarkers have been introduced to the clinic over the past 20 years. Each approach to ovarian cancer biomarker discovery has its own advantages and disadvantages and it seems likely that a global biomarker discovery platform that mines all possible sources for biomarkers might be more useful. Such data could be combined with information from relevant microarray data, bioinformatic analyses and literature searches. This proposed integrated systems biology approach has the potential to yield promising ovarian cancer markers for diagnosis, prognosis and monitoring of patients during therapy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20383179     DOI： 10.1038/nrc2831

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  58 in total

Review 1.  Phases of biomarker development for early detection of cancer.

Authors:  M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

2.  Lessons from controversy: ovarian cancer screening and serum proteomics.

Authors:  David F Ransohoff
Journal:  J Natl Cancer Inst       Date:  2005-02-16       Impact factor: 13.506

Review 3.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility.

Authors:  Nader Rifai; Michael A Gillette; Steven A Carr
Journal:  Nat Biotechnol       Date:  2006-08       Impact factor: 54.908

4.  An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.

Authors:  Ivo Meinhold-Heerlein; Dirk Bauerschlag; Yingyao Zhou; Lisa M Sapinoso; Keith Ching; Henry Frierson; Karen Bräutigam; Jalid Sehouli; Elmar Stickeler; Dominique Könsgen; Felix Hilpert; Constantin S von Kaisenberg; Jacobus Pfisterer; Thomas Bauknecht; Walter Jonat; Norbert Arnold; Garret M Hampton
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

Review 5.  Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited.

Authors:  J T Tamsma; H J Keizer; A E Meinders
Journal:  Ann Oncol       Date:  2001-10       Impact factor: 32.976

6.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

7.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs
Journal:  Lancet Oncol       Date:  2009-03-11       Impact factor: 41.316

8.  Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.

Authors:  Hsueh-Wei Chang; Shing M Lee; Steven N Goodman; Gad Singer; Sarah K R Cho; Lori J Sokoll; Fredrick J Montz; Richard Roden; Zhen Zhang; Daniel W Chan; Robert J Kurman; Ie-Ming Shih
Journal:  J Natl Cancer Inst       Date:  2002-11-20       Impact factor: 13.506

Review 9.  Promising directions for the diagnosis and management of gynecological cancers.

Authors:  E C Kohn; G B Mills; L Liotta
Journal:  Int J Gynaecol Obstet       Date:  2003-10       Impact factor: 3.561

Review 10.  Progress and challenges in screening for early detection of ovarian cancer.

Authors:  Ian J Jacobs; Usha Menon
Journal:  Mol Cell Proteomics       Date:  2004-02-05       Impact factor: 5.911
View more
  62 in total

1.  D-dimer as a potential prognostic marker.

Authors:  Zsuzsanna Nagy; Orsolya Horváth; Julia Kádas; Dorottya Valtinyi; Larisza László; Bence Kopper; György Blaskó
Journal:  Pathol Oncol Res       Date:  2012-07       Impact factor: 3.201

2.  Confounding effects of hormone replacement therapy in protein biomarker studies.

Authors:  Sharon J Pitteri; Samir M Hanash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-29       Impact factor: 4.254

3.  MicroRNA and transcription factor mediated regulatory network for ovarian cancer: regulatory network of ovarian cancer.

Authors:  Huanchun Ying; Jing Lv; Tianshu Ying; Jun Li; Qing Yang; Yuan Ma
Journal:  Tumour Biol       Date:  2013-08-29

4.  A microfluidic platform with digital readout and ultra-low detection limit for quantitative point-of-care diagnostics.

Authors:  Ying Li; Jie Xuan; Yujun Song; Ping Wang; Lidong Qin
Journal:  Lab Chip       Date:  2015-08-21       Impact factor: 6.799

5.  Targeted Proteomics for Multiplexed Verification of Markers of Colorectal Tumorigenesis.

Authors:  Anuli Christiana Uzozie; Nathalie Selevsek; Asa Wahlander; Paolo Nanni; Jonas Grossmann; Achim Weber; Federico Buffoli; Giancarlo Marra
Journal:  Mol Cell Proteomics       Date:  2017-01-04       Impact factor: 5.911

Review 6.  Strategies for discovering novel pancreatic cancer biomarkers.

Authors:  Alison Chan; Eleftherios P Diamandis; Ivan M Blasutig
Journal:  J Proteomics       Date:  2012-09-28       Impact factor: 4.044

7.  Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics.

Authors:  Simon Kaja; Jill D Hilgenberg; Julie L Collins; Anna A Shah; Debra Wawro; Shelby Zimmerman; Robert Magnusson; Peter Koulen
Journal:  J Biomed Opt       Date:  2012-08       Impact factor: 3.170

8.  Interpreting personal transcriptomes: personalized mechanism-scale profiling of RNA-seq data.

Authors:  Alan Perez-Rathke; Haiquan Li; Yves A Lussier
Journal:  Pac Symp Biocomput       Date:  2013

9.  Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.

Authors:  F Leung; A Dimitromanolakis; H Kobayashi; E P Diamandis; V Kulasingam
Journal:  Clin Biochem       Date:  2013-03-23       Impact factor: 3.281

10.  Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.

Authors:  Felix Leung; Marcus Q Bernardini; Marshall D Brown; Yingye Zheng; Rafael Molina; Robert C Bast; Gerard Davis; Stefano Serra; Eleftherios P Diamandis; Vathany Kulasingam
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-07-22       Impact factor: 4.254
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.